Showing results (191-200 of 227) with videos related to
Sort By:
Pageof 23
Blood Advances|October 21, 2021
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysisMehdi Hamadani, Ajay K Gopal, Marcelo Pasquini, et al.Nature|May 22, 2009
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1Kwan-Hyuck Baek, Alexander Zaslavsky, Ryan C Lynch, et al.Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.Bone Marrow Transplantation|July 26, 2020
90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.Blood|April 19, 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHLJordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, et al.Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.Pageof 23